Prognostic factors in patients with endocrine tumours of the duodenopancreatic area.
BACKGROUND
The development of endocrine tumours of the duodenopancreatic area (ETDP) is thought to be slow, but their natural history is not well known. The aim of this study was to determine the factors that influence survival of patients with ETDP.


METHODS
Eighty two patients with ETDP (44 non-functioning tumours, 23 gastrinomas, seven calcitonin-secreting tumours, four glucagonomas, three insulinomas, one somatostatinoma) followed from October 1991 to June 1997 were included in the study. The following factors were investigated: primary tumour size, hormonal clinical syndrome, liver metastases, lymph node metastases, extranodular/extrahepatic metastases, progression of liver metastases, local invasion, complete resection of the primary tumour, and degree of tumoral differentiation. The prognostic significance of these factors was investigated by uni- and multi-variate analysis.


RESULTS
Twenty eight patients (34%) died within a median of 17 months (range 1-110) from diagnosis. Liver metastases (p = 0.001), lymph node metastases (p = 0.001), progression of liver metastases (p < 0.00001), lack of complete resection of the primary tumour (p = 0.001), extranodular/extrahepatic metastases (p = 0.001), local invasion (p = 0.001), primary tumour size > or = 3 cm (p = 0.001), non-functioning tumours (p = 0.02), and poor tumoral differentiation (p = 0.006) were associated with an unfavourable outcome by univariate analysis. Multivariate analysis identified only liver metastases (risk ratio (RR) = 8.3; p < 0.0001), poor tumoral cell differentiation (RR = 8.1; p = 0.0001), and lack of complete resection of the primary tumour (RR = 4.8; p = 0.0007) as independent risk factors. Five year survival rates were 40 and 100% in patients with and without liver metastases, 85 and 42% in patients with and without complete resection of primary tumour, and 17 and 71% in patients with poor and good tumour cell differentiation respectively.


CONCLUSIONS
Liver metastases are a major prognostic factor in patients with ETDP. Progression of liver metastases is also an important factor which must be taken into account when deciding on the therapeutic approach. The only other independent prognostic factors are tumoral cell differentiation and complete resection of the primary tumour.
Madeira
I
I
Federation of Hepato-Gastroenterology, Hôpital Beaujon, Clichy, France.
Terris
B
B
Voss
M
M
Denys
A
A
Sauvanet
A
A
Flejou
J F
JF
Vilgrain
V
V
Belghiti
J
J
Bernades
P
P
Ruszniewski
P
P
D007516:Adenoma, Islet Cell / Q000401:mortality* / Q000601:surgery; D000328:Adult; D000368:Aged; D002116:Calcitonin / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010190:Pancreatic Neoplasms / Q000378:metabolism / Q000401:mortality* / Q000601:surgery; D011379:Prognosis; D012189:Retrospective Studies; D012306:Risk; D013005:Somatostatinoma / Q000401:mortality* / Q000556:secondary / Q000601:surgery; D015996:Survival Rate; D016896:Treatment Outcome
D002116:Calcitonin